Items related to Controlled Release Injection of a Central Nervous System...
Synopsis
Alzheimer’s disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer’s disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided into: Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae.
"synopsis" may belong to another edition of this title.
About the Author
Ibrahim Elsayed, PhD in pharmaceutics and industrial pharmacy from Cairo University. Postdoc research in drug delivery. Publications in international journals like; international journal of pharmaceutics and international journal of nanomedicine.
"About this title" may belong to another edition of this title.
Search results for Controlled Release Injection of a Central Nervous System...
Seller Image
Controlled Release Injection of a Central Nervous System Acting Drug
Published by
LAP LAMBERT Academic Publishing Nov 2014, 2014
ISBN 10: 3659633380
ISBN 13: 9783659633386
New
Taschenbuch
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Alzheimer's disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer's disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided into: Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae. 292 pp. Englisch. Seller Inventory # 9783659633386
Seller Image
Controlled Release Injection of a Central Nervous System Acting Drug
Published by
LAP LAMBERT Academic Publishing, 2014
ISBN 10: 3659633380
ISBN 13: 9783659633386
New
Softcover
Seller: moluna, Greven, Germany
Seller rating 5 out of 5 stars
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Elsayed IbrahimIbrahim Elsayed, PhD in pharmaceutics and industrial pharmacy from Cairo University. Postdoc research in drug delivery. Publications in international journals like international journal of pharmaceutics and internatio. Seller Inventory # 5169864
Buy New
£ 57.90
£ 41.53 shipping
Ships from Germany to U.S.A.
Ships from Germany to U.S.A.
Quantity: Over 20 available
Seller Image
Controlled Release Injection of a Central Nervous System Acting Drug
Published by
LAP LAMBERT Academic Publishing, 2014
ISBN 10: 3659633380
ISBN 13: 9783659633386
New
Taschenbuch
Seller: preigu, Osnabrück, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. Controlled Release Injection of a Central Nervous System Acting Drug | Ibrahim Elsayed (u. a.) | Taschenbuch | 292 S. | Englisch | 2014 | LAP LAMBERT Academic Publishing | EAN 9783659633386 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu. Seller Inventory # 104993056
Seller Image
Controlled Release Injection of a Central Nervous System Acting Drug
Published by
LAP LAMBERT Academic Publishing Nov 2014, 2014
ISBN 10: 3659633380
ISBN 13: 9783659633386
New
Taschenbuch
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Alzheimer's disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer's disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided into: Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 292 pp. Englisch. Seller Inventory # 9783659633386
Seller Image
Controlled Release Injection of a Central Nervous System Acting Drug
Published by
LAP LAMBERT Academic Publishing, 2014
ISBN 10: 3659633380
ISBN 13: 9783659633386
New
Taschenbuch
Seller: AHA-BUCH GmbH, Einbeck, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Alzheimer's disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer's disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided into: Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae. Seller Inventory # 9783659633386